GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: Forvisirvat is the INN for a sirtuin activator (WHO INN proposed list 133, July 2025). It is one of the compounds claimed in Sirtsei Pharmaceuticals' patent WO2021202822A1 [2]. The structure was disclosed as the sirtuin 6 activator clinical candidate SP-624 in early 2025, with suggested potential in psychiatric, neurodegenerative and metabolic disorders [3].
|
|
No information available. |
Summary of Clinical Use ![]() |
Forvisirvat (SP-624) is a clinical lead with anti-depressant potential. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04479852 | A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder | Phase 2 Interventional | Sirtsei Pharmaceuticals, Inc. | ||
NCT06254612 | A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Phase 2 Interventional | Sirtsei Pharmaceuticals, Inc. |